We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to ...

BioMed Realty, one of the biggest labspace owners in the Boston area, recently acquired 215 First St., 150 Second St. and 11 ...

Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...

SRPT insiders have traded $SRPT stock on the open market 6 times in the past 6 months. Of those trades, 3 have been purchases and 3 have been sales. Here’s a ...

Sarepta Therapeutics' Elevidys for DMD shows growing revenue potential, with management targeting >$3bn of total revenues in 2025, up 68% from 2024, led by gene therapy. Despite past valuation ...

(MENAFN- GlobeNewsWire - Nasdaq) The rising incidence of cancer is boosting the demand for advanced diagnostic tools, such as exosome-based diagnostics, which provide non-invasive and accurate ...

The US Food and Drug Administration (FDA) has taken a major step in addressing the nation’s chronic disease crisis by proposing a new front-of-package (FOP) nutrition label for most packaged foods.

Sarepta Therapeutics (NASDAQ:SRPT) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise ...

(Bloomberg) -- Approvals for drugs from Biogen Inc. and Sarepta Therapeutics Inc. show flaws in the process US drug regulators use to speed approval for drugs to fill unmet needs, federal ...